ZORYVE Wins 2025 Allure Best of Beauty Breakthrough Award

Arcutis Biotherapeutics’ ZORYVE® (roflumilast) was the recipient of Allure magazine’s 2025 Best of Beauty Breakthrough Award, marking the first time a prescription topical for atopic dermatitis (AD), plaque psoriasis, and seborrheic dermatitis has received the accolade.

With more than 1 million prescriptions, ZORYVE is currently the most prescribed branded topical for the three inflammatory skin conditions combined, according to a press release from Arcutis. The contains no ethanol, fragrances, propylene glycol, or other additives known to disrupt the skin barrier. The water-based, non-greasy vehicle also lacks penetration enhancers and ceramide-stripping agents, making it an alternative to traditional steroids and medicated shampoos.

“Allure’s recognition of ZORYVE underscores its uniquely broad therapeutic applicability and patient-centered formulation,” said Adam Friedman, MD, FAAD, Chair of Dermatology at The George Washington University School of Medicine & Health Sciences. “Its versatility, safety profile, and ability to treat multiple conditions with a single agent reflect innovation in topical drug delivery and dermatologic care.”

Source: Arcutis press release. September 17, 2021.